Transcript
Biomarker testing is a key component to the care of patients and may match patients to a personalized treatment plan.
Comprehensive biomarker testing should be considered at the time of diagnosis for all appropriate patients with advanced non small lung cancer or NSCLC, regardless of patient characteristics, and should test for all actionable molecular biomarkers and PD-L1.
Comprehensive biomarker testing using NGS rather than single gene testing may offer a more cost and tissue conscious approach and increase the likelihood of detecting a biomarker.
Generated biomarker testing reports should contain all... relevant information to help guide treatment plans.
Consider organizing your patient biomarker test results for easy retrieval and future reference in the event of disease recurrence or progression.
Multidisciplinary tumor boards can also assist in interpreting biomarker results.
Knowing your patient’s biomarker status may help you make more informed and personalized targeted treatment plans.
